SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.